Video

Dr. Shore on Benefits of Immunotherapy INO-5150 in Recurrent Prostate Cancer

​Neal D. Shore, MD, FACS, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

In a phase 1/2, open-label, multicenter study enrolled patients with biochemically recurrent prostate cancer and treated them with INO-5150, a DNA-based immunotherapy. This agent targets prostate-specific antigen and prostate-specific membrane antigen and was previously examined with or without plasmid-encoded cytokine adjuvant IL-12 (INO-9012). When it comes to recurrent prostate cancer, it is important to have options available, says Shore. Now, patients may have the option of receiving a daily pill rather than a required intramuscular or subcutaneous injection. This route of administration allows for patients to avoid a mandated trip to the hospital to receive the therapy, along with all the risks associated with COVID-19. 

The ability to take a once-daily pill is very convenient for patients, adds Shore. When a clinical evaluation is appropriate, then patients can met with their urologist, medical oncologist, or radiation oncologist. Overall, this kind of option provides patients with tremendous flexibility, and thus, it is a breakthrough in the treatment armamentarium for this patient population, concludes Shore.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP